ERBB2 and breast carcinoma: This intracellularly-delivered anti-GSDMB antibody effectively and specifically reduced GSDMB functions, thus providing a novel therapeutic strategy for HER2-positive breast cancers.427 The high expression of GSDMD was associated with tumor invasion and affected tumor size and stage.